Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival
Publication
, Conference
Richardson, PG; Kernan, NA; Grupp, SA; Martin, PL; Soiffer, RJ; Martin, R; Hannah, AL; Villa, KF
Published in: BLOOD
December 6, 2014
Duke Scholars
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 6, 2014
Volume
124
Issue
21
Location
San Francisco, CA
Publisher
AMER SOC HEMATOLOGY
Conference Name
56th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Richardson, P. G., Kernan, N. A., Grupp, S. A., Martin, P. L., Soiffer, R. J., Martin, R., … Villa, K. F. (2014). Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival. In BLOOD (Vol. 124). San Francisco, CA: AMER SOC HEMATOLOGY.
Richardson, Paul G., Nancy A. Kernan, Stephan A. Grupp, Paul L. Martin, Robert J. Soiffer, Richard Martin, Alison L. Hannah, and Kathleen F. Villa. “Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival.” In BLOOD, Vol. 124. AMER SOC HEMATOLOGY, 2014.
Richardson PG, Kernan NA, Grupp SA, Martin PL, Soiffer RJ, Martin R, et al. Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival. In: BLOOD. AMER SOC HEMATOLOGY; 2014.
Richardson, Paul G., et al. “Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival.” BLOOD, vol. 124, no. 21, AMER SOC HEMATOLOGY, 2014.
Richardson PG, Kernan NA, Grupp SA, Martin PL, Soiffer RJ, Martin R, Hannah AL, Villa KF. Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease: An Analysis of Clinical Benefit As Determined By Number Needed to Treat (NNT) to Achieve Complete Response and to Improve Survival. BLOOD. AMER SOC HEMATOLOGY; 2014.
Published In
BLOOD
EISSN
1528-0020
ISSN
0006-4971
Publication Date
December 6, 2014
Volume
124
Issue
21
Location
San Francisco, CA
Publisher
AMER SOC HEMATOLOGY
Conference Name
56th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology